Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $107
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on Haemonetics (NYSE:HAE) and raised the price target from $105 to $107.
May 10, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Haemonetics' Outperform rating is maintained by Barrington Research, with a price target increase from $105 to $107, indicating a positive outlook on the stock.
The maintenance of an Outperform rating combined with an increased price target suggests that Barrington Research has a positive outlook on Haemonetics' future performance. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100